View Older Stories View More Recent Stories
-
Johnson & Johnson (JNJ) call put ratio 2.1 call to 1 put into plans to separate Orthopaedics business
-
Johnson & Johnson plans to separate orthopaedics unit DePuy Synthes
-
Johnson & Johnson (JNJ) to separate orthopaedics business into standalone business operating as Depuy Synthes
-
Johnson & Johnson (JNJ) Tops Q3 EPS by 4c; lifts guidance
-
Jefferies flags Q3 earnings upside for this pharma giant as key drugs outperform
-
Protagonist Therapeutics (PTGX) Said to Be Mentioned Cautiously Regarding M&A
-
Johnson & Johnson (JNJ) call put ratio 1 call to 1 put into quarter results
-
Johnson & Johnson (JNJ) October straddle priced into quarter results
-
Protagonist Therapeutics (PTGX) PT Raised to $112 at BMO Capital
-
Protagonist Therapeutics stock surges after J&J acquisition talks report
-
Protagonist Therapeutics (PTGX) halted on volatility
-
Johnson & Johnson (JNJ) in talks to buy Protagonist Therapeutics (PTGX) - WSJ
-
Johnson & Johnson (JNJ) October 200 and 210 calls active into quarter results
-
Guggenheim Reiterates Buy Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) PT Raised to $212 at Goldman Sachs
-
Johnson & Johnson (JNJ) ordered to pay $966M after California jury finds company liable for woman's cancer in talc case - court filing
-
Johnson & Johnson icotrokinra meets primary endpoint in ulcerative colitis trial
-
Johnson & Johnson reports TREMFYA subcutaneous ulcerative colitis data
-
Johnson & Johnson reports contact lens study results at optometry meeting
-
Johnson & Johnson (JNJ) PT Raised to $200 at Wolfe Research
-
Johnson & Johnson (JNJ) PT Raised to $193 at Bernstein SocGen Group
-
UBS on why it's still not ready to push the buy button on pharma stocks
-
Wells Fargo sees 'room to run' for Johnson & Johnson, highlights pharma upside
-
Johnson & Johnson (JNJ) call put ratio 3.5 calls to 1 put with a focus on January 180 and April 185 calls
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
Trump on deal with Pfizer: we're going to be paying the lowest price, other drugmakers will commit in coming weeks
-
Guggenheim Reiterates Buy Rating on Johnson & Johnson (JNJ)
-
J&J's TREMFYA wins FDA approval for subcutaneous ulcerative colitis treatment
-
Rothschild upgrades Kenvue after Tylenol scare wipes $10 billion in market value
-
FDA issues warning letter to Johnson & Johnson (JNJ) after inspecting Janssen vaccine manufacturing facilities
-
Stifel: Electrophysiology Market Growth is Healthy
-
Guggenheim Upgrades Johnson & Johnson (JNJ) to Buy
-
CDC Panel Votes Against Requiring Prescriptions For Covid Shots - Bloomberg
-
CDC Panel Votes To End Universal Recommendation For Covid Shots - Bloomberg
-
Johnson & Johnson reports positive results from multiple myeloma study
-
Johnson & Johnson (JNJ) PT Raised to $186 at Goldman Sachs
-
Johnson & Johnson's icotrokinra outperforms rival drug in psoriasis trials
-
Guggenheim Reiterates Neutral Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) PT Raised to $195 at Wolfe Research, 'increased confidence in JNJ's upcoming talc litigation outcome'
-
Johnson & Johnson presents atrial fibrillation device study results
-
Buy this U.S. large-cap biopharma stock: JPMorgan
-
This MedTech stock is 'a strong buy under $500': Bernstein
-
Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
-
Johnson & Johnson launches AI bunion surgery system in U.S.
-
Johnson & Johnson seeks FDA approval for TREMFYA joint damage claims
-
FDA grants priority review to Johnson & Johnson's TAR-200 bladder cancer drug
-
Johnson & Johnson (JNJ): EU approves Darzalex as the first licensed treatment for patients with high-risk smouldering multiple myeloma
-
Erste Group Upgrades Johnson & Johnson (JNJ) to Buy
-
Johnson & Johnson submits FDA application for psoriasis drug icotrokinra
